1703-1801 - PROGRESS III - PTCY vs. TAC/MTX
- Protocol Short Name and Number: PROGRESS III – PTCY vs. TAC/MTX / Mi-Immune, 1703/1801
- Protocol Long Name:
- BMT CTN 1703: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
- BMT CTN 1801: Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel (BMT CTN 1703)
- BMT CTN # 1703 Co-Chair: Shernan Holtan, MD
- BMT CTN # 1703 Co-Chair: Javier Bolanos-Meade, MD
- BMT CTN # 1703 Protocol Officer: Mehdi Hamadani, MD
- BMT CTN # 1703 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1703@emmes.com
- Key Personnel (BMT CTN 1801)
- BMT CTN # 1801 Co-Chair: Miguel-Angel Perales, MD
- BMT CTN # 1801 Co-Chair: Leslie Kean, MD, PhD
- BMT CTN # 1801 Co-Chair: Ami Bhatt, MD, PhD
- BMT CTN # 1801 Protocol Officer: Wael Saber, MD, MS
- BMT CTN # 1801 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1703@emmes.com
- Keywords: PROGRESS, Mi-Immune, Graft versus Host Disease, GVHD Prophylaxis, GVHD, Post-Transplant Cyclophosphamide, PTCY, Microbiome, Allogeneic Transplant, Allo Transplant, Allo, Unrelated donor, Unrelated, Hematopoietic Stem Cell Transplant, HSCT, HCT, Quality of Life, QOL, Patient Reported Outcomes, PROs, Tacrolimus, TAC, Tacro, Methotrexate, MTX, Mycophenolate Mofetil, MMF, Acute Leukemia, Chronic Myelogenous Leukemia, CML, Myelodysplastic Syndrome, MDS, Chronic Myelomonocytic Leukemia, CMML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Leukemia